Lilly halts Alzheimer’s drug trial due to liver problems

By Ransdell Pierson (Reuters) – Eli Lilly and Co. said on Thursday it halted a mid-stage study of an experimental Alzheimer’s disease treatment due to potential liver toxicity, the latest setback in the quest to find a treatment that can slow or cure the memory-robbing condition. Lilly said the Phase II study of the drug, LY2886721, from a class known as beta secretase, or BACE, inhibitors, was stopped after safety monitors identified cases of abnormal liver tests. …